Bulletin
Investor Alert

New York Markets Close in:

Alexion Pharmaceuticals Inc.

NAS: ALXN

GO
/marketstate/country/us

Market open

 --Real time quotes

Feb 26, 2021, 1:49 p.m.

/zigman2/quotes/206262068/composite

$

152.53

Change

-1.12 -0.73%

Volume

Volume 719,744

Real time quotes

/zigman2/quotes/206262068/composite

Previous close

$ 153.65

$ 152.53

Change

-1.12 -0.73%

Day low

Day high

$151.60

$153.86

Open

52 week low

52 week high

$72.67

$162.60

Open

Company Description

Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma....

Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Valuation

P/E Current

56.53

P/E Ratio (with extraordinary items)

56.35

P/E Ratio (without extraordinary items)

57.48

Price to Sales Ratio

5.72

Price to Book Ratio

2.94

Price to Cash Flow Ratio

11.55

Enterprise Value to EBITDA

10.68

Enterprise Value to Sales

5.68

Total Debt to Enterprise Value

0.08

Efficiency

Revenue/Employee

1,580,714.00

Income Per Employee

157,258.00

Receivables Turnover

4.57

Total Asset Turnover

0.34

Liquidity

Current Ratio

3.59

Quick Ratio

3.11

Cash Ratio

1.89

Profitability

Gross Margin

86.69

Operating Margin

47.43

Pretax Margin

9.38

Net Margin

9.95

Return on Assets

3.39

Return on Equity

5.26

Return on Total Capital

20.17

Return on Invested Capital

4.28

Capital Structure

Total Debt to Total Equity

24.38

Total Debt to Total Capital

19.60

Total Debt to Total Assets

15.69

Long-Term Debt to Equity

22.86

Long-Term Debt to Total Capital

18.38

Officers and Executives

Name Age Officer Since Title
Dr. Ludwig N. Hantson 56 2017 Chief Executive Officer & Director
Dr. Aradhana Sarin 45 2017 Executive VP, Chief Strategy & Business Officer
Mr. Brian M. Goff 49 2017 Chief Commercial, Global Operations Officer & EVP
Mr. George Llado - 2015 Chief Information Officer & Senior Vice President
Dr. John J. Orloff 61 2017 Executive VP, Head-Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/17/2020 Daniel A. Bazarko
SVP, Controller, CAO
1,100   Disposition at $158 per share. 173,800
12/17/2020 Daniel A. Bazarko
SVP, Controller, CAO
13,066   Disposition at $157.76 per share. 2,061,292
12/17/2020 Daniel A. Bazarko
SVP, Controller, CAO
9,900   Disposition at $157.59 per share. 1,560,141
12/17/2020 Daniel A. Bazarko
SVP, Controller, CAO
11,000   Derivative/Non-derivative trans. at $140.16 per share. 1,541,760
12/17/2020 Daniel A. Bazarko
SVP, Controller, CAO
13,066   Derivative/Non-derivative trans. at $97.58 per share. 1,274,980
12/16/2020 Ludwig N. Hantson
CEO; Director
13,059   Derivative/Non-derivative trans. at $157.96 per share. 2,062,799
12/16/2020 Ludwig N. Hantson
CEO; Director
72,533   Derivative/Non-derivative trans. at $157.96 per share. 11,457,312
12/16/2020 Brian M. Goff
EVP & Chief Commercial Officer
3,261   Derivative/Non-derivative trans. at $157.96 per share. 515,107
12/16/2020 Brian M. Goff
EVP & Chief Commercial Officer
18,134   Derivative/Non-derivative trans. at $157.96 per share. 2,864,446
12/16/2020 John J. Orloff
EVP, Research & Development
3,261   Derivative/Non-derivative trans. at $157.96 per share. 515,107
12/16/2020 John J. Orloff
EVP, Research & Development
18,134   Derivative/Non-derivative trans. at $157.96 per share. 2,864,446
12/16/2020 Indrani M. Franchini
EVP, Chief Compliance Officer
2,913   Derivative/Non-derivative trans. at $157.96 per share. 460,137
12/16/2020 Indrani M. Franchini
EVP, Chief Compliance Officer
16,925   Derivative/Non-derivative trans. at $157.96 per share. 2,673,473
12/16/2020 Ellen V. Chiniara
EVP & Chief Legal Officer
2,988   Derivative/Non-derivative trans. at $157.96 per share. 471,984
12/16/2020 Ellen V. Chiniara
EVP & Chief Legal Officer
16,925   Derivative/Non-derivative trans. at $157.96 per share. 2,673,473
12/16/2020 Aradhana Sarin
EVP, CFO
2,510   Derivative/Non-derivative trans. at $157.96 per share. 396,479
12/16/2020 Aradhana Sarin
EVP, CFO
6,853   Derivative/Non-derivative trans. at $157.96 per share. 1,082,499
12/16/2020 Daniel A. Bazarko
SVP, Controller, CAO
1,725   Derivative/Non-derivative trans. at $157.96 per share. 272,481
12/16/2020 Daniel A. Bazarko
SVP, Controller, CAO
7,087   Derivative/Non-derivative trans. at $157.96 per share. 1,119,462
12/16/2020 Ludwig N. Hantson
CEO; Director
162,707   Award at $0 per share. 0
12/16/2020 Brian M. Goff
EVP & Chief Commercial Officer
40,677   Award at $0 per share. 0
12/16/2020 John J. Orloff
EVP, Research & Development
40,677   Award at $0 per share. 0
12/16/2020 Indrani M. Franchini
EVP, Chief Compliance Officer
37,965   Award at $0 per share. 0
12/16/2020 Ellen V. Chiniara
EVP & Chief Legal Officer
37,965   Award at $0 per share. 0
12/16/2020 Aradhana Sarin
EVP, CFO
15,371   Award at $0 per share. 0
12/16/2020 Daniel A. Bazarko
SVP, Controller, CAO
15,371   Award at $0 per share. 0
12/15/2020 John J. Orloff
EVP, Research & Development
40   Award at $93.53 per share. 3,741
12/15/2020 Ellen V. Chiniara
EVP & Chief Legal Officer
56   Award at $95.53 per share. 5,349
12/03/2020 Tanisha V. Cariño
EVP & CCAO
1,530   Disposition at $122.26 per share. 187,057
12/02/2020 Tanisha V. Cariño
EVP & CCAO
665   Derivative/Non-derivative trans. at $121.76 per share. 80,970
11/30/2020 Aradhana Sarin
EVP, CFO
1,298   Derivative/Non-derivative trans. at $124 per share. 160,952
06/08/2020 Brian M. Goff
EVP & Chief Commercial Officer
1,642   Derivative/Non-derivative trans. at $114.61 per share. 188,189
06/08/2020 John J. Orloff
EVP, Research & Development
2,784   Derivative/Non-derivative trans. at $114.61 per share. 319,074
06/08/2020 Anne-Marie Law
EVP, Chief Experience Officer
2,561   Derivative/Non-derivative trans. at $114.61 per share. 293,516
05/14/2020 Baker Bros. Advisors LP
Director
1,189   Award at $0 per share. 0
05/14/2020 Baker Bros. Advisors LP
Director
1,189   Award at $0 per share. 0
05/14/2020 Baker Bros. Advisors LP
Director
3,468   Award at $0 per share. 0
05/14/2020 Baker Bros. Advisors LP
Director
3,468   Award at $0 per share. 0
05/14/2020 Christopher J. Coughlin
Director
2,774   Award at $0 per share. 0
05/14/2020 Christopher J. Coughlin
Director
3,468   Award at $0 per share. 0
05/14/2020 Andreas Rummelt
Director
3,468   Award at $0 per share. 0
05/14/2020 David Richard Brennan
Director
2,428   Award at $0 per share. 0
05/14/2020 David Richard Brennan
Director
3,468   Award at $0 per share. 0
05/14/2020 John T. Mollen
Director
3,468   Award at $0 per share. 0
05/14/2020 Deborah L. Dunsire
Director
941   Award at $0 per share. 0
05/14/2020 Deborah L. Dunsire
Director
3,468   Award at $0 per share. 0
05/14/2020 Judith A. Reinsdorf
Director
595   Award at $0 per share. 0
05/14/2020 Judith A. Reinsdorf
Director
3,468   Award at $0 per share. 0
05/14/2020 Francois Nader
Director
941   Award at $0 per share. 0
05/14/2020 Francois Nader
Director
3,468   Award at $0 per share. 0
05/14/2020 Paul A. Friedman
Director
3,468   Award at $0 per share. 0
03/30/2020 Ludwig N. Hantson
CEO; Director
3,202   Derivative/Non-derivative trans. at $85.43 per share. 273,546
03/18/2020 Baker Bros. Advisors LP
Director
14,731   Acquisition at $83.14 per share. 1,224,735
03/18/2020 Baker Bros. Advisors LP
Director
1,331   Acquisition at $83.14 per share. 110,659
03/18/2020 Baker Bros. Advisors LP
Director
1,321   Acquisition at $82.92 per share. 109,537
03/18/2020 Baker Bros. Advisors LP
Director
119   Acquisition at $82.92 per share. 9,867
03/18/2020 Baker Bros. Advisors LP
Director
15,928   Acquisition at $82.13 per share. 1,308,166
03/18/2020 Baker Bros. Advisors LP
Director
1,439   Acquisition at $82.13 per share. 118,185
03/18/2020 Baker Bros. Advisors LP
Director
25,640   Acquisition at $81.79 per share. 2,097,095
03/18/2020 Baker Bros. Advisors LP
Director
2,314   Acquisition at $81.79 per share. 189,262
03/18/2020 Baker Bros. Advisors LP
Director
4,203   Acquisition at $81.47 per share. 342,418
03/18/2020 Baker Bros. Advisors LP
Director
380   Acquisition at $81.47 per share. 30,958
03/18/2020 Baker Bros. Advisors LP
Director
12,815   Acquisition at $81.09 per share. 1,039,168
03/18/2020 Baker Bros. Advisors LP
Director
1,158   Acquisition at $81.09 per share. 93,902
03/18/2020 Baker Bros. Advisors LP
Director
3,298   Acquisition at $80.91 per share. 266,841
03/18/2020 Baker Bros. Advisors LP
Director
298   Acquisition at $80.91 per share. 24,111
03/18/2020 Baker Bros. Advisors LP
Director
10,285   Acquisition at $79.87 per share. 821,462
03/18/2020 Baker Bros. Advisors LP
Director
929   Acquisition at $79.87 per share. 74,199
03/18/2020 Baker Bros. Advisors LP
Director
26,022   Acquisition at $79.72 per share. 2,074,473
03/18/2020 Baker Bros. Advisors LP
Director
2,351   Acquisition at $79.72 per share. 187,421
03/18/2020 Baker Bros. Advisors LP
Director
2,888   Acquisition at $79.29 per share. 228,989
03/18/2020 Baker Bros. Advisors LP
Director
261   Acquisition at $79.29 per share. 20,694
03/18/2020 Baker Bros. Advisors LP
Director
4,191   Acquisition at $79.16 per share. 331,759
03/18/2020 Baker Bros. Advisors LP
Director
379   Acquisition at $79.16 per share. 30,001
/news/latest/company/us/alxn

MarketWatch News on ALXN

  1. 5 Affordable Biopharma Stocks With Growth Potential

    12:06 p.m. Feb. 17, 2021

    - Josh Nathan-Kazis

  2. Alexion Pharmaceuticals downgraded to market perform from outperform at Raymond James

    7:48 a.m. Jan. 8, 2021

    - Tonya Garcia

  3. Stay bullish on the S&P 500

    11:48 a.m. Dec. 17, 2020

    - Lawrence G. McMillan

  4. Alexion Pharmaceuticals downgraded to hold from buy at Truist

    8:09 a.m. Dec. 16, 2020

    - Tomi Kilgore

  5. The Dow Fell 185 Points Because Risks Are Looking Bigger

    5:28 p.m. Dec. 14, 2020

    - Jacob Sonenshine

  6. Stocks Fell as U.S. Covid Deaths Surpass 300,000

    4:21 p.m. Dec. 14, 2020

    - Barbara Kollmeyer

  7. Alexion Pharmaceuticals downgraded to market perform from BMO Capital

    9:07 a.m. Dec. 14, 2020

    - Tomi Kilgore

  8. Alexion Pharmaceuticals stock soars 31% premarket after AstraZeneca buyout deal

    8:53 a.m. Dec. 14, 2020

    - Tomi Kilgore

  9. Alexion Pharmaceuticals downgraded to neutral from outperform at Wedbush

    8:35 a.m. Dec. 14, 2020

    - Tomi Kilgore

  10. Loading more headlines...
/news/nonmarketwatch/company/us/alxn

Other News on ALXN

  1. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus

    10:14 a.m. Today

    - Zacks.com

  2. Nasdaq ETF's Worst Day Since October: Stocks That Survived

    8:00 a.m. Today

    - Zacks.com

  3. Merger Arbitrage Mondays - Consolidation

    4:15 a.m. Feb. 22, 2021

    - Seeking Alpha

  4. BioCryst Short-Sellers Lose Control

    8:40 p.m. Feb. 21, 2021

    - Seeking Alpha

  5. John Paulson's Top 5 Buys of the 4th Quarter

    4:25 p.m. Feb. 19, 2021

    - GuruFocus.com

  6. Apellis Is A Long-Term Name To Own Based On PNH Data Alone

    5:07 a.m. Feb. 18, 2021

    - Seeking Alpha

  7. Top Merger Stocks Held By Fund Managers, Mid-Q1 2021

    12:55 p.m. Feb. 17, 2021

    - Seeking Alpha

  8. BioNano Genomics’ Next Double Won’t Come Easily

    10:39 a.m. Feb. 16, 2021

    - InvestorPlace.com

  9. Merger Arbitrage Mondays - Bidding War For Coherent Continues

    6:24 a.m. Feb. 15, 2021

    - Seeking Alpha

  10. Pick These 4 Low P/CF Stocks for a Value-Based Portfolio

    9:48 a.m. Feb. 12, 2021

    - Zacks.com

  11. ALXN vs. BMRN: Which Stock Is the Better Value Option?

    11:40 a.m. Feb. 11, 2021

    - Zacks.com

  12. 5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty

    10:30 a.m. Feb. 11, 2021

    - Zacks.com

  13. Palatin (PTN) Jumps: Stock Rises 8.7%

    9:59 a.m. Feb. 11, 2021

    - Zacks.com

  14. Elfun Trust Exits Chevron, Albemarle

    9:15 a.m. Feb. 11, 2021

    - GuruFocus.com

  15. Loading more headlines...

At a Glance

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard

Boston, Massachusetts 02210

Phone

1 4752302596

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$6.07B

Net Income

$603.40M

2020 Sales Growth

22.4%

Employees

3,837

/news/pressrelease/company/us/alxn

Press Releases on ALXN

  1. Celebrating the Alexion Charitable Foundation One Year Anniversary

    10:11 a.m. Today

    - 3BL Media

  2. Looking For Biotech Stocks To Buy Now? 4 Names To Know

    4:09 p.m. Feb. 24, 2021

    - StockMarket.com

  3. Health Equity at Alexion

    10:31 a.m. Feb. 23, 2021

    - 3BL Media

  4. Monoclonal Mouse Antibody Market Size to Surpass US$ 10300 million by 2025

    12:26 a.m. Feb. 19, 2021

    - Market Insight Reports

  5. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.